MarketPeel
Insider Trading Intelligence
Pricing
…
AS

Alfred Sandrock

VYGR
PRESIDENT AND CEO · VOYAGER THERAPEUTICS, INC. · CIK 0001577061
FILING MIX · LIFETIME39%/61%
BUYS
21
SELLS
33
TOTAL VALUE
$6.31M
COMPANIES
2
ACTIVE SINCE
Feb 2020
HOLDINGS NOW
482,718
AVG SELL PX
$46.18
TRADE KIND
SHOWING 54 / 54
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
12 backtested trades · 8 horizons · 15 pending
Forward-return performance of every backtestable P/S trade by Alfred Sandrock, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d12+50.00%-0.89%+0.21%-1.09%-1.25%—
14d12+58.33%+0.66%-0.52%+1.18%-0.76%—
30d12+58.33%+0.29%-0.72%+1.01%+1.99%—
60d12+66.67%-4.09%+0.25%-4.51%-8.51%—
90d12+58.33%-4.25%+6.44%-11.13%-17.92%—
180d12(4 pending)+87.50%-16.18%+11.02%-27.20%-29.11%—
1y12(4 pending)+75.00%-21.66%+18.04%-39.70%-40.17%—
2y12(7 pending)+100.00%-43.22%+25.38%-68.60%-88.05%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
VYGR · 472,549 shares · as of Apr 2, 2026
0235,150470,300705,450940,6002023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2020
2020
2020
2020
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 21 buys / 33 sellsCOVERAGE · 26 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
VYGR
VOYAGER THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
11,511$3.87$44.5K472,549Apr 2, 2026Apr 3, 2026 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
14,197$3.79$53.8K484,060Feb 24, 2026Feb 26, 2026 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
11,732$3.41$40.0K498,257Feb 18, 2026Feb 20, 2026 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
SALE
President and CEO
12,192$3.78$46.1K509,989Feb 10, 2026Feb 11, 2026 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
402,500——402,500Feb 6, 2026Feb 10, 2026 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
86,250——522,181Feb 6, 2026Feb 10, 2026 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
SALE
President and CEO
10,885$3.43$37.3K430,931Apr 2, 2025Apr 4, 2025 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
145,000——441,816Feb 21, 2025Feb 24, 2025 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
290,000——290,000Feb 21, 2025Feb 24, 2025 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
SALE
President and CEO
11,702$4.24$49.6K296,816Feb 20, 2025Feb 24, 2025 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
SALE
President & CEO
16,644$4.45$74.1K308,518Feb 11, 2025Feb 12, 2025 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
SALE
President and CEO
12,115$9.86$119.5K322,839Apr 2, 2024Apr 3, 2024 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
SALE
President and CEO
13,033$7.46$97.2K334,954Feb 21, 2024Feb 22, 2024 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
130,000——347,987Feb 9, 2024Feb 16, 2024 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
260,000——260,000Feb 9, 2024Feb 16, 2024 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
SALE
President and CEO
7,437$7.83$58.2K214,618Apr 3, 2023Apr 5, 2023 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
120,000——222,055Feb 17, 2023Feb 22, 2023 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
240,000——240,000Feb 17, 2023Feb 22, 2023 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
100,000——100,000Mar 22, 2022Mar 23, 2022 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
940,600——940,600Mar 22, 2022Mar 23, 2022 ↗View →
VYGR
VOYAGER THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
44,000——44,000Feb 7, 2022Feb 9, 2022 ↗View →
BIIB
BIOGEN INC.
SALE
Head of Research & Development
7,672$440.00$3.38M10,169.112Jun 7, 2021Jun 9, 2021 ↗View →
BIIB
BIOGEN INC.
PURCHASEGRANT
Stock grant
14,500——14,500Feb 18, 2021Feb 22, 2021 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
1,300——1,466Feb 12, 2021Feb 17, 2021 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
1,446——5,442Feb 12, 2021Feb 17, 2021 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
1,996——3,446Feb 12, 2021Feb 17, 2021 ↗View →
BIIB
BIOGEN INC.
PURCHASE
EVP, Research & Development
1,300——16,561.21Feb 12, 2021Feb 17, 2021 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
2,310——8,042Feb 12, 2021Feb 17, 2021 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
1,708——10,352Feb 12, 2021Feb 17, 2021 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
642$278.03$178.5K18,496.21Feb 12, 2021Feb 17, 2021 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
1,466——0Feb 12, 2021Feb 17, 2021 ↗View →
BIIB
BIOGEN INC.
PURCHASE
EVP, Research & Development
1,446——18,007.21Feb 12, 2021Feb 17, 2021 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
758$278.03$210.7K17,738.21Feb 12, 2021Feb 17, 2021 ↗View →
BIIB
BIOGEN INC.
PURCHASE
EVP, Research & Development
1,708——19,715.21Feb 12, 2021Feb 17, 2021 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
577$278.03$160.4K19,138.21Feb 12, 2021Feb 17, 2021 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
1,533$278.03$426.2K15,261.21Feb 12, 2021Feb 17, 2021 ↗View →
BIIB
BIOGEN INC.
PURCHASEGRANT
Stock grant
3,728——16,794.21Jan 27, 2021Jan 29, 2021 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
1,500$350.00$525.0K13,066.21Nov 4, 2020Nov 6, 2020 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
915——0Feb 15, 2020Feb 19, 2020 ↗View →
BIIB
BIOGEN INC.
PURCHASE
EVP, Research & Development
1,213——15,019.245Feb 15, 2020Feb 19, 2020 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
538$333.00$179.2K14,481.245Feb 15, 2020Feb 19, 2020 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
1,213——915Feb 15, 2020Feb 19, 2020 ↗View →
BIIB
BIOGEN INC.
PURCHASE
EVP, Research & Development
1,422——13,464.245Feb 12, 2020Feb 14, 2020 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
2,211——0Feb 12, 2020Feb 14, 2020 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
660$331.76$219.0K12,042.245Feb 12, 2020Feb 14, 2020 ↗View →
BIIB
BIOGEN INC.
PURCHASE
EVP, Research & Development
2,211——12,702.245Feb 12, 2020Feb 14, 2020 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
538$331.76$178.5K12,926.245Feb 12, 2020Feb 14, 2020 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
703$331.76$233.2K13,806.245Feb 12, 2020Feb 14, 2020 ↗View →
BIIB
BIOGEN INC.
PURCHASE
EVP, Research & Development
1,583——14,509.245Feb 12, 2020Feb 14, 2020 ↗View →
BIIB
BIOGEN INC.
PURCHASEGRANT
Stock grant
12,060——12,060Feb 12, 2020Feb 14, 2020 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
1,583——8,747Feb 12, 2020Feb 14, 2020 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
1,422——4,106Feb 12, 2020Feb 14, 2020 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
1,859——6,888Feb 12, 2020Feb 14, 2020 ↗View →
BIIB
BIOGEN INC.
SALE
EVP, Research & Development
1,340——2,766Feb 12, 2020Feb 14, 2020 ↗View →
Other insiders · VYGR
Loading peer insiders…
About this filer
CIK 0001577061
ROLE
President and CEO
PRIMARY
VYGR
COMPANIES
2
ACTIVE SINCE
Feb 2020
MARKETPEEL · /INSIDER/0001577061DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback